Skip to main content
. 2025 Apr 22;64(5):743–756. doi: 10.1007/s40262-025-01496-2

Table 2.

Estimates of population pharmacokinetic parameters of the final model

Parameter Final model Bootstrap
Mean RSE (%) Shrinkage (%) Median 95% CI
Remdesivir
 CL (L/h) 105 17.8 100 69.3–154
 V (L) 121 23.7 111 45.9–195.5
GS-441524
 CL/fm (L/h) 15.9 8.39 16.0 13.2–19.6
 V/fm (L) 429 11.4 429 353–512
 Age effect on V –1.15 33.7 –1.18 – 2.82 to – 0.51
 eGFR effect on CL 1.12 0.02 1.23 0.78–1.89
Between subject variability (%)
 Remdesivir CL 53.1 29.5 10.0 45.4 9.03–77.7
 Remdesivir V 61.4 31.2 12.8 60.2 14.6–122
 GS-441524 CL/fm 36.8 17.7 6.91 34.4 20.1–50.1
 GS-441524 V/fm 46.0 22.1 –5.52 40.4 18.9–67.5
Error model parameter
 Remdesivir additive residual (µM) 0.014 38.1 0.016 0.0008–0.039
 Remdesivir proportional error 0.62 17.2 0.61 0.44–0.74
 GS-441524 proportional error 0.16 7.06 0.16 0.11–0.20

CL, clearance; CI, confidence interval;  fm, fraction of remdesivir metabolized to GS-441524; RSE, relative standard error; V, volume of distribution